I have been thinking about Black Friday and holiday
I have been thinking about Black Friday and holiday wishes… I know what I want and if things work out we should be able to attain the beginnings of my wish this coming year. If you’re listening Santa here is what I want…
The 200 million shares opens the possibilities of not only securing our financing of our trials and purchase of Leronlimab from Samsung. If the next few catalysts do what we hope they do in securing a accent to a much higher stock price. Then the possibilities run rampant with my wish. More stock price value gives us independence to grow our company quickly with larger purchases of Leronlimab. To give us that jolt of not having to wait for the revenue to come before we repurchase again and again. Once revenue starts making a large purchase is priority to kick starting this company in the right direction. Having the funds to do it before waiting 90 days for revenue to show as companies usually pay within that time period. Could be a real slow down. It’s a big opportunity to be able to finance a quicker purchase and grow grow grow…
If you’re wondering what my wish is and you know from my past posts. It will be no surprise. My wish is we become our own pharmaceutical company and grow grow grow. This coming year is our year for a few approvals and after two approvals my dream becomes true I believe. Give us two approvals in Cancer and a few Covid indications and throw in a late BLA approval in HIV and my dream of my wish very much becomes true. Why is that you say? Because after a couple of quick approvals this year… nobody will be able to afford to buy us out. We will grow into our own big Pharma and grow into a top 10 in the world if not top 3 on so many Block Buster Indications we have defined. We don’t need any partners in any indication either. Let me say that again… we don’t need any partners!!!
This coming year is so exciting and yet we wait patiently as we have for the past few years. The difference is… we know trial results that are not just good but very good. This is a huge difference in waiting for a BLA and knowing we met the primary end point but just can’t get the handle on filing the BLA. A much approved position to be in.
We have taken the science of Leronlimab to new levels with better defined trials that have shown us proven results in Cancer mTNBC, Nash, HIV, Covid and even solid tumor cancers. Maybe even all cancers as we become an oncology company. We have many more autoimmune indications to look forward to also.
Our recent trials results can’t be denied and now just need to be explored a tiny bit more before we are well on our way. We hope this year produces BTD’s and BLA’s and a few quick EUA’s. Every indication trialed has been fast tracked process approved or will be including the Covid EUA temporary approval processes.
If you haven’t paid attention to the possibilities of what fast tracked means or says about our molecule… it say to me that the FDA recognizes the importance of the results of the molecule and wants to help us get there in approving it for each faster process we apply for. Ground breaking recognition. The 13d and shorts don’t want you to believe we have a good relationship with the FDA but if we did not have a good relationship… would we get all these faster processing approval processes? I don’t think so. So now is the time to believe in what we have and our future in my opinion.
If I am right then not only does my dream become true but we all become very well off with this investment. I believe by years end of 2022 we approach $100/share. That is just the beginning and I believe in a four figure stock price some day and that could be 5 years or maybe a tiny bit longer… but sooner than later when you do the math on each market indication as we seek Block Buster drug approvals on a true platform drug potential.
I know I am thankful to be invested in this miracle molecule. Recognizing the opportunities is just the start of knowing where we are headed. The future is so bright… we all have something to be thankful for this fine holiday.
Happy Holidays to you and yours and a very Happy Thanksgiving. Dream a little… dream of summer houses and boats and RV’s and international travel… this is what I dream about. Yes I am a true optimist and have optimistic opinions of Leronlimab. Live a little and and enjoy the possibilities we have before us… just dream a little!
13
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Diving Headfirst into Holiday Tech Splurging The holiday hustle is upon us, folks, and Epson's stepping up with early Black Friday deals that'll have tech heads scrambling. They’re cutting prices up to $250 on their swanky home lineup—projectors, printers, scanners, you name it. This ain't just about making someone else smile, though; it's about the sweet spot where...
Continue Reading
A Social Revolution in King of Prussia Look, this ain't your typical bar review. We're talking about the Uncanny Comics and Kava Bar at King of Prussia Mall—where comic books, collectible treasures, and good company collide with a South Pacific vibe. Kava: Beyond Just Another Drink First off, if you're scratching your head about kava, don't fret. It's a beverage made...
Continue Reading
Dan Tyler's Role: Meeting a Growing Demand When it comes to expanding your reach in the business world, bringing fresh blood to the team isn't just about filling a seat—it's about filling the needs of your market. That's exactly what Chronograph is doing by appointing Dan Tyler as their Client Development Director in London. Tyler's experience is like a Swiss army knife...
Continue Reading
Breaking Ground in Surgical Oncology In a world where surgical precision teeters between sight and touch, Ziva Surgical has staked its claim. Popping out of its shell like a tenacious crab, the folks formerly known as OncoRes Medical are done just playing in the lab. Turns out, a bit of Australian grit can shake up global surgery practices — who knew? Bringing Science...
Continue Reading
Questioning the Value of Recent Deals It seems like everyone's wearing rose-colored glasses when a fancy deal gets announced. But dig beneath the headlines, and you might find shareholders grumbling if firms like Penske Automotive Group, Accelerant Holdings, and Distribution Solutions Group are getting short-changed. The crux? Insiders making a pretty penny while ordinary...
Continue Reading
Setting the Stage: Minerva Foods' Latest Report Walking through the jungle of financial statements, few things are clear-cut. Minerva Foods handed out its latest report, stirring both optimism and concern among the suits at the table. Here's the brass tacks of it: a 9.5% boost in net revenue drumming up R$56.2 billion over twelve months. Sounds solid, huh? Yet, lurking...
Continue Reading
Porsche Atlanta Northwest Joins Group 1 Automotive This ain't just some humdrum industry announcement, folks. Group 1 Automotive, the Houston-based heavyweight, has tightened its grip on the Atlanta car scene by welcoming Porsche Atlanta Northwest into the fold. This development marks the latest notch in Group 1’s belt as they continue gobbling up Atlanta-area...
Continue Reading
UMG Steps into the Spotlight at Morgan Stanley Event Music, money, and technology—it's a compelling trio. Universal Music Group (EURONEXT: UMG) is sending its heavyweights, Matt Ellis and Michael Nash, to the Morgan Stanley European Technology, Media & Telecom Conference on November 18, 2026. This isn't just any run-of-the-mill industry hobnob. We're talking about the...
Continue Reading
Economic Wrangling: What Happened? Here comes Frasle Mobility, standing tall against a tide trying to pull everyone under. Ending the third quarter of 2026, they dropped a modest net revenue of R$1.38 billion. A light dip of 1.9% year-over-year, but don't let that fool you. Amid the chaos, these folks managed to expand their gross margin and kept their financials...
Continue Reading
Honoring Progress in Medication Safety Boy, if there's one thing that's clear in the world of healthcare, it's that nothing's more vital than patient safety. The Institute for Safe Medication Practices (ISMP) is more than a fine-toothed comb in that realm; it's basically the gold standard. Every year, they shine a light on folks and organizations wrestling with the beast...
Continue Reading
Top 5 Most Recently Viewed Articles
Massive Earnings Jump Catches Eye Hey, not every day you see a company hitting a century mark in growth, is it? Acer Inc. (TWSE: 2353) just blew the doors off their financial results. We're not just talking about incremental gains here. They slapped down a Q2 net income of NT$2.17 billion—up a whopping 100.2% from last year. It's like they found the turbo button on this...
Continue Reading
Amtrak's Call for Early Thanksgiving Bookings Reserve tickets now for the best fares and guaranteed seats With Thanksgiving approaching, Amtrak is urging travelers to secure their tickets early to lock in the best prices before they sell out. Last year, millions chose America's Railroad during the holiday season, highlighting the importance of early planning. This year,...
Continue Reading
Avenir LNG Limited made waves back when it announced a major transformation aimed squarely at shipping and trading operations. This pivot was no half-baked idea; they looked to solidify their position by possibly listing on Euronext Growth Oslo. Why? Because demand for liquefied natural gas (LNG) was surging globally, and Avenir wanted to be front and center. Key Moves:...
Continue Reading
Understanding Small-Cap Stocks and Their Growth Potential Investing in small-cap stocks offers both risks and rewards. These stocks are generally associated with smaller companies that can fluctuate more than their larger counterparts, often providing higher returns for those willing to navigate their volatility. Recently, the landscape appears more favorable for these...
Continue Reading
Jotne Connect Launches New AI Unit for Digital Engineering Jotne Connect, a notable subsidiary of the Jotne Group and a recognized leader in engineering data solutions, is excited to introduce a revolutionary Artificial Intelligence (AI) unit. This innovative department aims to innovate extensively in Model-Based Systems Engineering (MBSE), Product Lifecycle Management...
Continue Reading